中国社区医师
中國社區醫師
중국사구의사
Chinese Community Doctors
2014年
22期
15-15,17
,共2页
结核分枝杆菌%耐药性%分析
結覈分枝桿菌%耐藥性%分析
결핵분지간균%내약성%분석
Mycobacterium tuberculosis%Drug resistance%Analysis
目的:分析本地区结核分枝杆菌的耐药状况,指导临床合理用药,以减少耐药菌的产生。方法:采用酸性罗氏培养法对结核分枝杆菌培养阳性标本进行抗结核药物耐药分析。结果:412例结核培养阳性标本中,158例耐药,总耐药率38.35%(158/412)。单耐药108例,单耐药率26.21%(108/412),以耐链霉素(SM/S)最多10.92%(45/412),158例耐药标本中至少耐异烟肼(INH/H)、利福平(RFP/R)两种药的有20例,耐多药率4.85%(20/412)。结论:本地区结核分枝杆菌耐药状况值得重视,应进一步加强结核病患者的归口管理,推行全程化疗督导。
目的:分析本地區結覈分枝桿菌的耐藥狀況,指導臨床閤理用藥,以減少耐藥菌的產生。方法:採用痠性囉氏培養法對結覈分枝桿菌培養暘性標本進行抗結覈藥物耐藥分析。結果:412例結覈培養暘性標本中,158例耐藥,總耐藥率38.35%(158/412)。單耐藥108例,單耐藥率26.21%(108/412),以耐鏈黴素(SM/S)最多10.92%(45/412),158例耐藥標本中至少耐異煙肼(INH/H)、利福平(RFP/R)兩種藥的有20例,耐多藥率4.85%(20/412)。結論:本地區結覈分枝桿菌耐藥狀況值得重視,應進一步加彊結覈病患者的歸口管理,推行全程化療督導。
목적:분석본지구결핵분지간균적내약상황,지도림상합리용약,이감소내약균적산생。방법:채용산성라씨배양법대결핵분지간균배양양성표본진행항결핵약물내약분석。결과:412례결핵배양양성표본중,158례내약,총내약솔38.35%(158/412)。단내약108례,단내약솔26.21%(108/412),이내련매소(SM/S)최다10.92%(45/412),158례내약표본중지소내이연정(INH/H)、리복평(RFP/R)량충약적유20례,내다약솔4.85%(20/412)。결론:본지구결핵분지간균내약상황치득중시,응진일보가강결핵병환자적귀구관리,추행전정화료독도。
Objective:To analyze drug resistance status of mycobacterium tuberculosis in this region,and to guide rational drug use in clinical,in order to reduce the generation of drug-resistant bacteria.Methods:We analyzed the resistance of anti-tb drug for mycobacterium tuberculosis culture positive specimens using acidic roche culture method.Results:Among 412 cases of TB culture positive specimens,158 cases of drug resistance,the total resistance rate was 38.35%(158/412).108 cases of single drug resistance,the single resistance rate was 26.21%(108/412).Streptomycin resistance was highest(SM/S) up to 10.92%(45/412),In 158 specimens of drug resistant,20 cases at least resistant to isoniazid(INH)/H),rifampicin(RFP)/R) of those two kinds of medicine, the multi-drug resistance rate was 4.85% (20/412).Conclusion:In this area,it is worth to pay attention to the condition of drug-resistant on mycobacterium tuberculosis.We should further strengthen TB patients under centralized management,and promote the whole supervision of chemotherapy.